Lipitor no better than Zocor
Pfizer failed to get a new marketing advantage for its top-selling cholesterol drug Lipitor, after a new study showed no significant reduction in "major coronary events" versus rival treatment Zocor.
The five-year study found no statistically significant difference between the cholesteral reducing drugs Lipitor and US drugmaker Merck's Zocor in reducing heart disease-related death, heart attack and cardiac arrest. Results of the study were presented on Tuesday at an American Heart Association conference.
The new study compared the highest dose of Lipitor to relatively average doses of Zocor in who had had a previous heart attack.
Lipitor had 17 per cent fewer non-fatal heart attacks in the study versus patients on Zocor, and significant reduction in other heart problems requiring medical attention. But there was no difference in the overall death rate between the two treatments.
November 20, 2005 in Cholesterol - Statin | Permalink | Comments (1)
Crestor Lawsuit
The cholesterol lowering drug Crestor (rosuvastatin) is reported by the consumer group Public Citizen to be implicated in cases of kidney damage and rhabdomyolysis, an adverse reaction involving the destruction of muscle tissue that can lead to kidney failure. There are numerous drug lawsuits and class action lawsuits currently in place against Vioxx and other drugs.
May 27, 2005 in Cholesterol - Statin, Crestor | Permalink | Comments (0)
